10
Participants
Start Date
October 6, 2017
Primary Completion Date
May 28, 2019
Study Completion Date
May 28, 2019
SyB C-1101
SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice daily (840 mg before breakfast and 280 mg before dinner. SyB C-1101 will be administered orally twice daily for 21 consecutive days, followed by a 7-day observation period. The treatment period of 28 days (21 days of administration + 7 days of observation) constitutes 1 cycle.
Research Site, Nagoya
Research Site, Maebashi
Research Site, Sapporo
Research Site, Kobe
Research Site, Kurashiki
Research Site, Shinagawa
Research Site, Fukuoka
Research Site, Kumamoto
Research Site, Kyoto
Lead Sponsor
SymBio Pharmaceuticals
INDUSTRY